Clinical trials: Moderate Respiratory Distress
Moderate Respiratory Distress, Severe Respiratory Distress
High Flow Nasal Oxygen Therapy an Implementation Study in Pediatric Wards
The purpose of this study is to prospectively evaluate the process of implementing HFNO in several MSF projects, varying according to geographical and programmatic contexts, population, health structures, human resources, and…
- Trial name
- HFNO (NCT06715423)
- Where
- Afghanistan
- Volunteers
- 960 people
- Sponsor
- Epicentre
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
Respiratory Distress Syndrome, Positive-Pressure Respiration
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability
This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung…
- Conditions
- Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation
- Trial name
- NCT06430554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Mild to Moderate Acute Respiratory Distress Syndrome
Post-Market Study of Low-flow ECCO2R Using PrismaLung+
PrismaLung+ is intended to provide extracorporeal carbon dioxide removal (ECCO2R) as a standalone therapy or in combination with continuous renal replacement therapy (CRRT).
- Trial name
- NCT04617093
- Testing
- PrismaLung+
- Where
- 10 sites in France
- Volunteers
- 63 people
- Sponsor
- Vantive Health LLC
Acute Respiratory Distress Syndrome, Respiration, Artificial
Impact of Decreasing Respiratory Rate on Lung Injury Biomarkers in ARDS Patients
Acute respiratory distress syndrome (ARDS) is a form of acute lung injury of inflammatory origin, which represents a public health problem worldwide due to its prevalence, and its high mortality rate, close to 40%.
- Conditions
- Acute Respiratory Distress Syndrome, Respiration, Artificial, Ventilator-Induced Lung Injury
- Trial name
- NCT04641897
- Testing
- Respiratory rate modification
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Pontificia Universidad Catolica de Chile
ARDS (Moderate or Severe)
Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate whether inhaled nitric oxide (iNO), added to standard care, can reduce mortality in adults with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- ENARCT-ARDS (NCT07334873)
- Testing
- Inhaled Nitric Oxide Therapy
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Respiratory Distress Syndrome, Ventilator Lung
FCV vs PCV in Moderate to Severe ARDS
The goal of this clinical trial is to compare flow-controlled ventilation (FCV) and pressure-controlled ventilation (PCV) in patients with moderate to severe acute respiratory distress syndrome on the intensive care unit.
- Trial name
- NCT06051188
- Testing
- Flow-controlled ventilation
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Erasmus Medical Center
ARDS, TTM
TwichView-guided Atricurium Dose Adjustment Trial
The goal of this clinical trial is to learn if using a monitor that measures muscle response can lower the amount of muscle relaxant medicine needed in adults who are treated in an intensive care unit (ICU) and need a continuous…
- Conditions
- ARDS, TTM, ECMO, Neuromuscular Blockade Monitoring
- Trial name
- NCT07807046
- Testing
- EMG-based quantitative TOF-guided atracurium titration
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Fu Jen Catholic University Hospital
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
Acute Respiratory Distress Syndrome
Effect of APRV and LTV on Lung Ventilation and Perfusion in Patients With Moderate-to-severe ARDS
Low tidal volume ventilation (LTV) has been proposed and widely used in patients with acute respiratory distress syndrome (ARDS) to prevent ventilator-induced lung injury (VILI) and mitigate its effects.
- Trial name
- NCT05767125
- Testing
- APRV, LTV
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Respiratory Distress Syndrome, Adult, Sars-CoV2
Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of ~40%, and has no known treatment other than optimization of support.
- Trial name
- CHILL-pilot (NCT03376854)
- Testing
- Hypothermia, Neuromuscular Blocking Agents, Standard of Care
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
ARDS (Acute Respiratory Distress Syndrome)
Continuous vs Bolus Neuromuscular Blockade Regimens in Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA)
Current clinical guidelines, such as those from the Surviving Sepsis Campaign and ARDSNet, recommend short-term NMBA use for patients with moderate to severe ARDS who exhibit persistent ventilator dyssynchrony or high plateau…
- Trial name
- COBRA (NCT07567768)
- Testing
- Neuromuscular Blocking Agent - Bolus Dosing, Neuromuscular Blocking Agent - Continuous Infusion
- Volunteers
- 100 people
- Sponsor
- University of Calgary
COVID-19, ARDS
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…
- Conditions
- COVID-19, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04452097
- Testing
- Human umbilical cord mesenchymal stem cells + best supportive care
- Sponsor
- Baylx Inc.
Septic Shock, Severe Sepsis
Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Severe sepsis/septic shock is a serious condition associated with high mortality rate. Hydrocortisone has been recommended as a useful treatment to decrease mortality in hemodynamically unstable septic shock patients, not…
- Conditions
- Septic Shock, Severe Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01284452
- Testing
- Hydrocortisone
- Where
- Thailand
- Volunteers
- 197 people
- Sponsor
- Mahidol University
Ventilator-Induced Lung Injury
Physiological Effects of Controlled vs. Assisted Ventilation During Moderate-to-severe ARDS (PEARL Study)
Background: In patients with acute hypoxemic respiratory failure or ARDS, mechanical ventilation is often required. Two common strategies are pressure support ventilation (PSV), which allows spontaneous breathing, and…
- Trial name
- PEARL (NCT07315815)
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acute Respiratory Distress Syndrome
Noninvasive Positive Pressure Ventilation in Moderate Acute Respiratory Distress Syndrome
In order to identify the effect of noninvasive positive pressure ventilation (NPPV) on decreasing inflammatory response, improving the pathophysiological manifestation and reducing the morbidity and mortality in the moderate…
- Trial name
- NCT01585922
- Testing
- noninvasive positive pressure ventilation (NPPV), invasive mechanical ventilation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Hospital
Acute Respiratory Distress Syndrome
Prediction of Duration of Mechanical Ventilation in ARDS
The investigators are planning to perform a secondary analysis of an academic dataset of 1,303 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) included in several published cohorts (NCT00736892…
- Trial name
- PIONEER (NCT05993377)
- Testing
- Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .
- Where
- 20 sites in Spain, United Kingdom
- Volunteers
- 1,303 people
- Sponsor
- Hospital Universitario de Gran Canaria Doctor Negrín
ARDS, Lung Protective Ventilation
Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse alveolar injury caused by a variety of pulmonary and extrapulmonary factors, leading to refractory hypoxemia. It has high incidence and mortality rates.
- Trial name
- ARDS (NCT06514209)
- Testing
- cisatracurium
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Southeast University, China
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.